Eli Lilly and Company Share Price Today: Live Updates & Key Insights

Eli Lilly and Company share price today is $977.33, up -2.26%. The stock opened at $993.45 against the previous close of $999.84, with an intraday high of $993.45 and low of $973.16.

Eli Lilly and Company Share Price Chart

Eli Lilly and Company

us-stock
To Invest in {{usstockname}}
us-stock

Eli Lilly and Company Share Price Performance

$977.33 -0.0226(-2.26%) LLY at 13 Mar 2026 01:59 PM Drug Manufacturers - General
Lowest Today 973.16
Highest Today 993.45
Today’s Open 993.45
Prev. Close 999.84
52 Week High 1132.06
52 Week Low 620.46
Day’s Range: Low 973.16 High 993.45
52-Week Range: Low 620.46 High 1132.06
1 day return -
1 Week return -1.31
1 month return -6.04
3 month return -7.99
6 month return +30.54
1 year return +22.02
3 year return +201.11
5 year return +416.57
10 year return -

Eli Lilly and Company Institutional Holdings

Lilly Endowment Inc 10.32

Vanguard Group Inc 9.18

BlackRock Inc 7.37

PNC Financial Services Group Inc 5.75

State Street Corp 3.89

Vanguard Total Stock Mkt Idx Inv 3.00

FMR Inc 2.88

Capital Research Global Investors 2.81

JPMorgan Chase & Co 2.30

Vanguard 500 Index Investor 2.27

Geode Capital Management, LLC 2.22

Morgan Stanley - Brokerage Accounts 1.70

Capital World Investors 1.68

T. Rowe Price Associates, Inc. 1.51

Wellington Management Company LLP 1.50

State Farm Mutual Automobile Ins Co 1.40

NORGES BANK 1.35

American Funds Growth Fund of Amer A 1.31

Capital Group Growth Fnd of Amer Comp 1.31

Bank of America Corp 1.28

iShares Core S&P 500 ETF 1.13

Fidelity 500 Index 1.13

Capital Research & Mgmt Co - Division 3 1.12

State Street® SPDR® S&P 500® ETF 1.05

PRIMECAP Management Company 1.04

Vanguard Growth Index Investor 1.01

Northern Trust Corp 1.00

American Funds Invmt Co of Amer A 0.76

Capital Group Investment Co of Amer Comp 0.76

The Goldman Sachs Group Inc 0.75

State Street®HlthCrSelSectSPDR®ETF 0.66

Vanguard PRIMECAP Inv 0.61

Vanguard Institutional Index I 0.51

Vanguard Dividend Appreciation ETF 0.49

American Funds Washington Mutual A 0.48

Capital Group Wash Mutual Invtrs Comp 0.48

State St S&P 500® Indx SL Cl III 0.47

Loomis Sayles Long Corp Disc Alpha 0.46

American Funds AMCAP A 0.44

Capital Group AMCAP Composite 0.44

Eli Lilly and Company Market Status

Strong Buy: 16

Buy: 7

Hold: 4

Sell: 1

Strong Sell: 1

Eli Lilly and Company Fundamentals

Market Cap 894875.60 M

PB Ratio 33.6988

PE Ratio 43.6611

Enterprise Value 929432.96 M

Total Assets 112476.00 M

Volume 2340074

Eli Lilly and Company Company Financials

Annual Revenue FY25:65179000000 65179.0M, FY24:45042700000 45042.7M, FY23:32072500000 32072.5M, FY22:28541400000 28541.4M, FY21:28318400000 28318.4M

Annual Profit FY25:54615000000 54615.0M, FY24:36624400000 36624.4M, FY23:25230200000 25230.2M, FY22:21911600000 21911.6M, FY21:21005600000 21005.6M

Annual Net worth FY25:20638300000 20638.3M, FY24:10590000000 10590.0M, FY23:4988400000 4988.4M, FY22:6244800000 6244.8M, FY21:5581700000 5581.7M

Quarterly Revenue Q4/2025:19292000000 19292.0M, Q3/2025:17600800000 17600.8M, Q2/2025:15557700000 15557.7M, Q1/2025:12728500000 12728.5M, Q4/2024:13532800000 13532.8M

Quarterly Profit Q4/2025:16408300000 16408.3M, Q3/2025:14592500000 14592.5M, Q2/2025:13109900000 13109.9M, Q1/2025:10504300000 10504.3M, Q4/2024:11129000000 11129.0M

Quarterly Net worth Q4/2025:6636000000 6636.0M, Q3/2025:5582500000 5582.5M, Q2/2025:5660500000 5660.5M, Q1/2025:2759300000 2759.3M, Q4/2024:4409800000 4409.8M

About Eli Lilly and Company & investment objective

Company Information Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Organisation Drug Manufacturers - General

Employees 50000

Industry Drug Manufacturers - General

CEO Mr. David A. Ricks

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right